Status:

COMPLETED

Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression

Lead Sponsor:

Eli Lilly and Company

Conditions:

Depression

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purposes of this study are to determine: * The safety of duloxetine and any side effects that might be associated with it. * How duloxetine compares to escitalopram and placebo (an inactive ingre...

Detailed Description

duloxetine 60mg - 120mg, escitalopram 10mg - 20mg, and placebo, 8-month,

Eligibility Criteria

Inclusion

  • Must be at least 18 of age
  • Must meet the criteria for major depressive disorder
  • You must be able to visit the doctor's office about once a week for 2 to 3 months. After that, you will need to visit the doctor's office once a month for about 6 months
  • You must be able to take the study drug as prescribed (6 capsules per day taken once-daily)

Exclusion

  • You are a woman and are pregnant or breastfeeding.
  • You have a current or previous major psychiatric disorder other than depression, such as bipolar disorder, schizophrenia, or other psychotic disorder.
  • You have a history of alcohol or drug dependence within the past 6 months

Key Trial Info

Start Date :

November 1 2003

Trial Type :

INTERVENTIONAL

End Date :

May 1 2005

Estimated Enrollment :

675 Patients enrolled

Trial Details

Trial ID

NCT00073411

Start Date

November 1 2003

End Date

May 1 2005

Last Update

July 31 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.

Cincinnati, Ohio, United States